IMB-101 is a bispecific antibody targeting OX40L and TNF, which simultaneously modulates adaptive and innate immune responses. This novel therapeutic approach addresses significant unmet medical needs for various autoimmune disease patients, including those with rheumatoid arthritis who are non-responsive or resistant to anti-TNF agents.

OX40L is a key regulator of the immune system, activating and inducing the differentiation of T cells, and contributing to autoantibody production. Although various drugs have been developed to inhibit TNF, a major cytokine observed in RA patients, the ACR70 response rate remains below 50%, indicating unsatisfactory efficacy. IMB-101 is an innovative immunomodulatory antibody drug that simultaneously targets TNF and OX40L, thereby inducing short-term inflammation reduction and achieving long-term immune system equilibrium.

By simultaneously blocking TNF and OX40L, superior therapeutic effects compared to Humira have been confirmed in in vitro, ex vivo, and in vivo studies.